ABBOTT PARK, Ill., Aug. 28, 2017 — Abbott (NYSE: ABT) announced today it has received U.S. Food and Drug Administration (FDA) approval for its Full MagLev™ HeartMate 3™ Left Ventricular Assist System (also known as an LVAD).

Over the past quarter-century, the worldwide burden of rheumatic heart disease has declined although high rates of the illness persist in certain poor regions, including Oceania, South Asia and sub-Saharan Africa, a new study finds.

Men with early-stage prostate cancer who receive androgen deprivation therapy are at significantly higher risk for heart failure, according to a study published in the British Journal of Cancer.

Plenty plenty of research has shown sitting down at work can present health problems. But a recent study from a team in Canada examined how prolonged standing at work can impact one’s risk for cardiovascular disease (CVD)—and the results were surprising. Those who stand are at a much greater risk for CVD.

Funding for cardiac arrest (CA) research lags far behind other leading causes of death in the United States, according to research published in the Journal of the American Heart Association.

A new clinical trial is underway to test a closed-chest procedure designed to treat patients with ischemic cardiomyopathy.

According to a new study, hearts from donors between 10 and 14 years old can be safely transplanted into adults and are also associated with a reduced risk of cardiac allograft vasculopathy (CAV).

Medication was effective in treating nearly 40 percent of heart failure patients experiencing functional mitral regurgitation (FMR) with reduced ejection fraction (HFrEF), according to a new study in JACC: Heart Failure.